IGM and Sanofi collaboration will pivot to immunology and inflammation
IGM Biosciences has announced that the focus of its exclusive worldwide collaboration agreement with Sanofi will now shift to developing…
IGM Biosciences has announced that the focus of its exclusive worldwide collaboration agreement with Sanofi will now shift to developing…
Marinus Pharmaceuticals has announced that its pivotal Phase III RAISE study (NCT04391569) of IV ganaxolone for the treatment of status…
Rallybio has announced a collaboration with the pharma giant to advance complementary therapeutic solutions for foetal and neonatal alloimmune thrombocytopenia…
Pfizer has reported positive top-line results from its Phase III MONeT study (NCT05842967) evaluating the efficacy of single-dose Abrysvo for…
Though a recent Phase III trial failed to achieve its primary endpoint with Imfinzi (durvalumab) in a specific subset of…
Following Bavarian Nordic’s announcement of the US commercial launch of its mpox (monkeypox) vaccine Jynneos (Imvanex/Imvamune), Morris & Dickson has…
As Eli Lilly’s plans for its Alzheimer’s medication donanemab get delayed, Eisai has submitted a supplemental Biologics License Application (sBLA)…
Soon after GSK gained traction with a US Food and Drug Administration (FDA) fast track designation for its investigational treatment…
Johnson & Johnson (J&J) is allegedly looking to strengthen its presence in the cardiovascular device market with the acquisition of…
Amneal Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved an abbreviated new drug application (ANDA) for…